Advertisement
Advertisement
U.S. Markets open in 3 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.57+1.29 (+6.06%)
At close: 04:00PM EDT
22.20 -0.37 (-1.64%)
After hours: 06:36PM EDT
Advertisement

Agios Pharmaceuticals, Inc.

88 Sidney Street
2nd Floor
Cambridge, MA 02139-4169
United States
617 649 8600
https://www.agios.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees390

Key Executives

NameTitlePayExercisedYear Born
Dr. Jacqualyn A. Fouse Ph.D.CEO & Director1.27MN/A1961
Mr. Jonathan Biller J.D.CFO & Head of Corp. Affairs769.33kN/A1965
Dr. Bruce Car Ph.D.Chief Scientific Officer894.8kN/A1962
Dr. Lewis Clayton Cantley Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1949
Dr. Tak Wah MakCo-Founder & Member of Scientific Advisory BoardN/AN/A1946
Dr. Craig B. ThompsonCo-Founder & Chairman of Scientific Advisory BoardN/AN/A1953
Dr. Shin-San Su Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1956
Mr. T. J. Washburn Jr.Principal Accounting OfficerN/AN/A1981
Dr. Clive Patience Ph.D.Chief Technical Operations OfficerN/AN/A1964
Ms. Kendra AdamsVP of External Communications & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Agios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement